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Abstract
Introduction:  Irritable  bowel  syndrome  (IBS)  is  characterized  by  recurrent  abdominal  pain,
bloating,  and  changes  in  bowel  habit.
Aims:  To  determine  the  clinical  effectiveness  of  the  antispasmodic  agents  available  in  Mexico
for the  treatment  of  IBS.
Methods:  We  carried  out  a  systematic  review  and  meta-analysis  of  randomized  controlled
clinical trials  on  antispasmodic  agents  for  IBS  treatment.  Clinical  trials  identiﬁed  from  January
1960 to  May  2011  were  searched  for  in  MEDLINE,  the  Cochrane  Library,  and  in  the  Clinical-
Trials.gov  registry.  Treatment  response  was  evaluated  by  global  improvement  of  symptoms  or
abdominal pain,  abdominal  distention/bloating,  and  frequency  of  adverse  events.  The  effect
of antispasmodics  vs  placebo  was  expressed  in  OR  and  95%  CI.
Results:  Twenty-seven  studies  were  identiﬁed,  23  of  which  fulﬁlled  inclusion  criteria.  The  stud-
ied agents  were  pinaverium  bromide,  mebeverine,  otilonium,  trimebutine,  alverine,  hyoscine,
alverine/simethicone,  pinaverium/simethicone,  fenoverine,  and  dicyclomine.  A  total  of
2585 patients  were  included  in  the  meta-analysis.  Global  improvement  was  1.55  (CI  95%:  1.33
to 1.83).  Otilonium  and  the  alverine/simethicone  combination  produced  signiﬁcant  values  in
global improvement  while  the  pinaverium/simethicone  combination  showed  improvement  in
bloating.  As  for  pain,  2394  patients  were  included  with  an  OR  of  1.52  (IC  95%:  1.28  a  1.80),
favoring antispasmodics.
Conclusions: Antispasmodics  were  more  effective  than  placebo  in  IBS,  without  any  signiﬁcantion  of  simethicone  improved  the  properties  of  the  antispasmodicadverse events.  The  addit
agents, as  seen  with  the  alverine/simethicone  and  pinaverium/simethicone  combinations.
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Efecto  de  los  antiespasmódicos  solos  o  combinados  en  el  tratamiento  del  Síndrome
de  Intestino  Irritable:  revisión  sistemática  y  meta-análisis
Resumen
Introducción:  El  Síndrome  de  Intestino  Irritable  (SII)  se  caracteriza  por  distensión  y  dolor
abdominal  recurrentes,  además  de  cambios  en  el  patrón  defecatorio.
Objetivo: Deﬁnir  la  utilidad  clínica  de  los  antiespasmódicos  disponibles  en  México  para  el
tratamiento  del  SII.
Métodos: Se  realizó  una  revisión  sistemática  y  meta-análisis  de  ensayos  clínicos  controlados
aleatorios  de  fármacos  antiespasmódicos  para  el  tratamiento  del  SII.  Se  identiﬁcaron  los  ensayos
de enero  1960  a  mayo  de  2011,  para  esto  se  realizó  una  búsqueda  bibliográﬁca  en  MEDLINE,
the Cochrane  Library  y  en  el  sitio  de  registro  clinicaltrials.gov.  Se  tomaron  como  puntos  a  eval-
uar: evaluación  global,  mejoría  de  los  síntomas,  como  dolor  y  distensión  abdominal,  así  como
los efectos  adversos  del  tratamiento.  El  efecto  de  los  fármacos  antiespasmódicos  vs  placebo  se
expresó como  RM  e  IC  95%.
Resultados: Veintisiete  estudios  fueron  identiﬁcados,  de  los  cuales  23  cumplieron  los  cri-
terios de  inclusión.  Los  medicamentos  estudiados  fueron  pinaverio,  mebeverina,  otilonio,
trimebutina,  alverina,  hioscina,  alverina/simeticona,  pinaverio/simeticona,  fenoverina  y  dici-
clomina.  Un  total  de  2585  pacientes  fueron  incluidos  en  el  meta-análisis.  La  mejoría  global  fue
de 1,55  (IC  95%:  1,33  a  1,83).  Otilonio  y  alverina/simeticona  tienen  resultados  que  favorecen
la mejoría  global,  la  combinación  de  pinaverio/simeticona  mostró  mejoría  en  el  alivio  de  la
distensión.  Respecto  a  mejoría  del  dolor,  se  incluyeron  2.394  con  un  OR  de  1,52  (IC  95%:  1,28  a
1,80) a  favor  de  los  antiespasmódicos  en  general.
Conclusiones:  Los  antiespasmódicos  son  más  eﬁcaces  que  el  placebo  en  el  SII,  sin  efectos
secundarios  signiﬁcativos.  La  adición  de  simeticona  parece  que  mejora  las  propiedades  de
los antiespasmodicos,  tal  es  el  caso  de  las  combinaciones  de  alverina/simeticona  y  pinave-
rio/simeticona.
© 2011  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
Todos los  derechos  reservados.
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Irritable  bowel  syndrome  (IBS)  is  a  frequent  gastrointestinal
functional  disorder  in  the  western  world  and  Mexico  is  not
an  exception.1 It  is  characterized  by  recurrent  abdominal
pain,  bloating,  and  defecation  disorders.2,3 The  pathophys-
iology  of  IBS  is  not  yet  fully  understood4,5;  but  increased
pain  sensitivity  and  altered  small  bowel  and  colon  motility
are  main  factors  contributing  to  IBS  symptoms.  When  com-
pared  with  healthy  controls,  IBS  patients  demonstrate  both
visceral  hypersensitivity  and  hyper-reactive  motility.6
Antispasmodic  agents  are  believed  to  reduce  pain  associ-
ated  with  IBS  through  the  inhibition  of  contractile  pathways
in  the  gut  wall  and  to  improve  bowel  habits  by  increas-
ing  colonic  transit  time,  therefore  reducing  stool  passage
frequency.  Previous  meta-analyses7,8 have  proven  the  use-
fulness  of  antispasmodics  alone  in  the  treatment  of  IBS.
Nonetheless,  antispasmodic  availability  differs  among  coun-
tries.  In  the  United  States,  the  American  College  of
Gastroenterology  review  concluded  that  data  were  insufﬁ-
cient  for  making  a  recommendation  as  to  the  effectiveness
of  the  available  antispasmodic  agents.9 In  Europe  for  exam-
ple,  the  utility  of  the  available  antispasmodics  has  been
evaluated,10 however,  there  is  no  information  regarding  the
effectiveness  of  those  available  in  Latin  America.  Therefore,
we  conducted  a  systematic  review  of  antispasmodic  agents,
both  alone  and  in  combination,  for  the  treatment  of  IBS,  and
carried  out  a  meta-analysis  of  the  data  obtained.  This  was
d
r
c
ione to  determine  the  clinical  effectiveness  of  the  available
ntispasmodic  agents  as  sole  formulations  or  in  combination
ith  simethicone,  and  to  update  the  current  information  on
BS  treatment  in  Mexico.
ethods
o  determine  the  antispasmodic  agents  that  are  avail-
ble  in  Mexico,  we  reviewed  the  therapeutic  index  of  the
ictionary  of  Medical  Specialties  (Diccionario  de  Especiali-
ades  Médicas),  PLM®,  Mexico-2011.  We  focused  the  search
n  section  A3  of  the  index  that  lists  all  the  agents  for
unctional  gastrointestinal  disorders.  The  identiﬁed  anti-
pasmodics  were  further  searched  for  in  a  systematic  review
onducted  in  MEDLINE,  Cochrane  Library,  and  ClinicalTri-
ls.gov  from  January  1960  to  May  2011  and  in  abstracts
resented  at  the  Digestive  Disease  Week  (DDW)  and  the
exican  Disease  Week  (Semana  Nacional  de  Gastroen-
erología)  from  2010-2011.  The  agents  listed  in  Table  1
ere  analyzed.  Accordingly,  the  search  terms  were  Irri-
able  Bowel  Syndrome  and  the  following  antispasmodics:
inaverium  bromide,  mebeverine,  otilonium,  trimebutine,
lverine,  hyoscine,  alverine/simethicone,  pinaverium  bro-
ide/simethicone,  alverine/simethicone,  fenoverine,  and
icyclomine.  Two  physicians  conducted  the  search,  then
eviewed  the  results  and  resolved  the  existing  dis-
repancies.  Figure  1  explains  the  selection  process  for
ncluding  papers  in  the  meta-analysis.  Articles  selected
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Table  1  Clinical  trials  on  antispasmodics  that  fulﬁlled  inclusion  criteria.
Author  and  year Medication  Teatment  period
(weeks)
Diagnostic  criteria  Jadad
Levy  197727 Pinaverium  bromide  150  mg  2  Clinical  3
Delmont 198128 Pinaverium  bromide  150  mg  4  Clinical  4
Connell 196529 Mebeverine  400  mg  12  Clinical  5
Tasman- Jones  197330 Mebeverine  400  mg  4  Clinical  4
Berthelot 198131 Mebeverine  400  mg  8  Clinical  4
Kruis 198632 Mebeverine  400  mg  16  Clinical  4
Secco 198333 Mebeverine  400  mg  4  Clinical  4
Enck 200534 Mebeverine  Not  reported 4 Clinical 4
Barbier 198135 Otilonium  320  mg 2 Clinical 3
Clave 201120 Otilonium  120  mg 15 Rome  II 5
Baldi 199136 Otilonium  120  mg  4  Clinical  2
Bataglia 199837 Otilonium  120  mg  15  Clinical  3
Castiglione 199138 Otilonium  120  mg  12  Clinical  2
Glende 200239 Otilonium  120  mg  15  Clinical  3
Clave 201121 Otilonium  120  mg  15  Rome  II  5
Ritchie 197940 Hyoscine  40  mg  4  Clinical  4
Nigam 199441 Hyoscine  40  mg  4  Clinical  3
Shafer 199042 Hyoscine  30  mg  4  Clinical  3
Fielding 198043 Trimebutine  600  mg  24  Clinical  3
Moshal 197944 Trimebutine  600  mg  4  Clinical  4
Luttecke 197545 Trimebutine  600  mg  3  (days)  Clinical  2
Lutecke 198046 Trimebutine  300  mg  3  (days)  Clinical  2
Mitchell 200247 Alverine  120  mg  12  (days)  Clinical ¿ ?
Wittmann 201048 Alverine/simethicone  60/300  mg 4  Rome  III  5
Page 198149 Dicycloverine  160  mg  2  Clinical  4
Remes-Troche  201123,
Schmulson  201124
Pinaverium/simethicone  200/600  mg 12  Rome  III  5
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supplemented  with  speciﬁc  investigations  when  needed.
Antispasmodic  agents  versus  placebo  studies  were  included
when  there  was  a  minimum  14-day  treatment  period.  Treat-The table shows all trials initially considered for analysis. Those w
dosages are described.
or  review  were  those  in  which  the  authors  employed
he  same  inclusion  criteria.  Afterwards,  the  studies  were
eexamined  to  conﬁrm  that  they  fulﬁlled  the  inclu-
ion  criteria.  Finally,  the  meta-analysis  was  conducted
ccording  to  predetermined  protocols  and  following  the
tandard  recommendations  proposed  by  Sack  et  al.11
hese  recommendations  consist  of  a  rigorous  review  which
ncludes  the  aspects  listed  in  Table  2.  When  information
as  lacking,  we  contacted  the  authors  for  its  comple-
ion.
996 potential studies identified
in electronic databases.
166 from Pubmed,
6 from Cochrane,
747 from Google and DDW
Abstracts,
9 from clinical tr ials.   
453 reports excluded based on
title and abstract.
237 studies excluded because of
duplication.   
215 reports excluded for:
comparing active agents,
crossover studies, inadequately
explained outcome, low J adad
score.    
Figure  1  Review  process  ﬂowchart.
ma Jadad score below 3 were subsequently eliminated. Total daily
nclusion  criteria
he  following  criteria  were  used  for  selecting  the  stud-
es:  Randomized  controlled  trials  that  included  subjects
ver  16  years  of  age,  a  diagnosis  of  IBS  based  on  accepted
linical  criteria  (Rome  I,  II  or  III),  or  diagnostic  criteriaent  response  was  evaluated  by  the  global  improvement
Table  2  Recommendations  by  Sacks  for  conducting  a  meta-
analysis.
Search  of  the  literature
List  of  trials  analyzed
Treatment  assignment
Ranges  of  patient  characteristics,  diagnoses  and  treatments
Combinability  criteria
Measurement
Control  and  Measurement  of  potential  bias
Statistical  analysis
Sensitivity  analysis
Application  of  results
Remaining  problems
Effect  of  antispasmodic  agents  in  the  treatment  of  Irritable  Bowel  Syndrome:  Systematic  review  and  meta-analysis  85
Table  3  Jadad  Score  Items.
Item  Score
Was  the  study  described  as
randomized  (this  includes  words
such  as  randomly,  random,  and
randomization)?
0/1
Was  the  method  used  to  generate  the
sequence  of  randomization
described  and  appropriate  (table
of random  numbers,
computer-generated,  etc.)?
0/1
Was the  study  described  as  double
blind?
0/1
Was  the  method  of  double  blinding
described  and  appropriate
(identical  placebo,  active  placebo,
dummy,  etc.)?
0/1
Was there  a  description  of
withdrawals  and  dropouts?
0/1
Deduct  one  point  if  the  method  used
to  generate  the  sequence  of
randomization  was  described  but
was  inappropriate  (patients  were
allocated  alternately,  or  according
to  date  of  birth,  hospital  number,
etc.)*
−1
Deduct  one  point  if  the  study  was
described  as  double  blind  but  the
method  of  blinding  was
inappropriate  (e.g.,  comparison  of
tablet  vs.  injection  with  no  double
dummy)*
−1
0,0
0,2
0,4
0,6
0,8
-3 -2 -1 0 1
Log peto odds ratio
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and  otilonium  was  observed.  The  OR  for  otilonium  was  2.030=No; 1=Yes; −1=Point deduction*
of  symptoms  or  abdominal  pain  (reported  by  patients  or
physicians),  abdominal  distention/bloating,  and  frequency
of  adverse  events.  Methodological  quality  was  evaluated
using  the  Jadad  scale12 (Table  3).  This  scoring  scale  eval-
uates  each  trial  according  to  the  quality  of  the  scientiﬁc
description  of  the  randomization  method.  The  scale  ranges
from  0  to  5  points:  A  score  of  2  or  less  is  considered  low
quality  and  3  or  higher  is  considered  high  quality.12--14 The
present  review  only  included  studies  with  a  Jadad  score  of
3  or  above.
Statistical  analysis
The  Critical  Appraisal  Skills  Program  (CASP)  was  used  with
Excel  for  Windows  2000  (Microsoft,  USA)  for  calculating
the  meta-analysis,  and  the  Comprehensive  Meta-Analysis
V2© by  Biostat,  Inc.  was  also  used.  Each  analysis  was  run
in  accordance  with  standard  methodological  procedures
using  the  following  determinations:  a  test  of  heterogeneity15
between  active  versus  control  group  results.  This  was  con-
sidered  signiﬁcant  when  p<0.10  and/or  the  value  of  I2 >25%.
Antispasmodic  efﬁcacy  was  deﬁned  according  to  the  Peto
method.16 In  addition,  a  funnel  plot  graph17 was  used  to
evaluate  publication  bias.  Finally,  the  Number  Needed  to
(
a
bigure  2  Publication  bias  assessment  funnel  plot  for  trials
onsidered  in  overall  improvement.
reat  (NNT)18 was  determined  using  the  formula  NNT=1-TBE
1-OR)/TBE  divided  by  TBE  (1-TBE)  (1-OR).
esults
ncluded  randomized  clinical  trials
 total  of  450  publications  were  identiﬁed  from  1960  to
011.  Twenty-seven  studies  fulﬁlled  the  inclusion  crite-
ia  and  23  were  included  in  the  meta-analysis  after  the
adad  score  was  determined.  Nine  speciﬁc  agents  were
ested  as  monotherapies,  plus  the  alverine/simethicone
nd  pinaverium/simethicone  combinations.  For  the  global
ssessment  endpoint,  a  total  of  2585  patients  were  included;
297  were  allocated  to  active  treatment  groups  and  1288
o  the  placebo  group.  Of  these  trials,  6  studied  mebever-
ne,  7  otilonium,  3  hyoscine,  2  trimebutine,  one  alverine
lus  simethicone  (alverine/simethicone),  one  dicyclomine,
 pinaverium  bromide,  and  one  pinaverium  bromide  plus
imethicone  (pinaverium  bromide/simethicone).  Despite
he  systematic  search  for  trials  with  high  quality  criteria,  not
ll  trials  reported  the  effect  on  all  the  studied  outcomes,  i.e.
lobal  assessment,  pain,  abdominal  distention/bloating,  and
dverse  events,  and  therefore  a  different  number  of  trials
as  considered  for  each  tested  variable.
Heterogeneity  testing  was  not  signiﬁcant  (p≥0.05),
llowing  the  use  of  the  Peto  method  and  ﬁxed  effects.
ublishing  bias  evaluation  was  tested  using  the  funnel  plot
hown  in  Figures  2  and  3.
eta-analysis
atient  global  assessment
f  the  27  trials  included  for  the  global  assessment  analy-
is,  only  18  had  sufﬁcient  data  for  consideration.  The  total
ample  included  2585  patients,  with  1297  allocated  to  the
reatment  group.  Global  assessment  with  an  OR  of  1.55
nd  a  95%CI  of  1.33  to  1.83  was  conﬁrmed  for  all  antispas-
odics  (Fig.  4).  Based  on  the  Peto  method,  a signiﬁcant
ifference  favoring  the  alverine/simethicone  combination95%  CI  1.49-2.77),  and  was  1,76  (95%CI  1.18-2.61)  for  the
lverine/simethicone  combination.  The  OR  for  pinaverium
romide  was  1.48  (95%CI  0.95-4.63),  as  shown  in  Figure  4.
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Aigure  3  Publication  bias  assessment  funnel  plot  of  trials  con-
idered  for  pain  relief.
ercentage  of  patients  with  abdominal  pain
mprovement
 total  of  13  trials  contained  enough  data  to  evaluate  pain
elief.  They  included  a  total  of  2394  patients,  1053  allocated
o  otilonium  and  409  to  the  alverine/simethicone  combi-
ation  treatment;  both  providing  the  highest  number  of
atients  for  a  particular  therapy.  Antispasmodics  tested  for
bdominal  pain  relief  showed  an  OR  of  1,52  (95%CI  1.28  to
.80),  favoring  these  agents  when  compared  with  placebo.
omplete  results  are  shown  in  Figure  5.
ercentage  of  patients  with  abdominal
istention/bloating  relief
he  results  for  the  efﬁcacy  analysis  of  abdominal  dis-
ention/bloating  relief  are  shown  in  Figure  6;  however,
ew  trials  appropriately  report  this  effect.  Although
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fﬁcacy  is  borderline  with  an  OR  of  1.455  (95%CI  1.17-1.81),
here  is  a  consistent  trend  of  antispasmodics  as  a  group
o  relieve  abdominal  distention/bloating.  The  combination
inaverium/simethicone  showed  an  OR  of  1.455  (95%CI  1.11-
.91).
ate  of  adverse  events  (safety)
he  OR  for  the  antispasmodic  treatment  group  was  0.738
95%  CI  0.54-0.98).  Results  are  shown  in  Figure  7.  Previous
eta-analyses7,8,19 have  shown  antispasmodic  treatments  to
e  safe.  All  trials  included  in  the  present  meta-analysis  con-
istently  showed  safety,  corroborating  the  safe  proﬁle  for
hese  agents  demonstrated  in  the  most  recent  reports.20,21
umber  Needed  to  Treat  (NNT)
he  NNT  was  calculated  only  for  the  antispasmodics  showing
 signiﬁcant  value  of  10  in  global  assessment  (95%  CI  6.0-
1.0).  The  NNT  for  global  improvement  was  7  for  Otilonium
nd  8  for  Alverine/simethicone  and  8  and  11  for  pain  relief,
espectively.
iscussion
ecision-making  in  medical  practice  today  often  requires
nswers  to  concrete  questions.  In  1976  Glass22 proposed
 set  of  different  statistical  tests  in  the  meta-analysis  for
uantitative  and  qualitative  analyses  based  on  results  from
ndependent  trials.  Previous  studies  mention  the  discrep-
ncy  among  different  trials  due  to  a  lack  of  uniformity  in
iagnostic  criteria.  In  the  present  analysis,  we  decided  to
emove  those  trials  that  had  a  Jadad  score  below  3,  in  other
ords,  of  low  quality  (Table  3).  We  felt  that  an  analysis  of
ow  quality  trials  could  be  a  signiﬁcant  source  of  bias  for  the
nterpretation  of  results.
25/200 96/198
96/198
33/49
33/49
25/84
14/48
91/178
130 / 310
24/33
1/22
16/24
12/40
7/24
60/143
3/36
66/165
36/160
105/361
17/30
17/25
34/55
103/122
103/122
17/30
4/20
21/50
582/1288
25/200
21/48
21/48
38/84
22/48
06/182
66/314
31/36
11/22
8/32
6/40
15/24
71/154
10/36
90/160
58/157
58/353
24/30
19/25
43/55
07/123
07/123
13/30
11/20
24/50
15/1297
reatment Control
Peto odds ratio and 95% CI
Favours placebo
0,01 0,1 1 10 10 100
Favours treatment
 vertical  bars  represent  the  difference  in  the  response  rates
s  represent  the  OR  and  the  horizontal  lines  the  95%CI.  Overall
diamonds.  Antispasmodics  were  effective  on  the  global  assess-
icone.
Effect  of  antispasmodic  agents  in  the  treatment  of  Irritable  Bowel  Syndrome:  Systematic  review  and  meta-analysis  87
Group  by
Compa rison
Stud y Drug Statistics  for ea ch stud y Odds ratio and  95% CI
Odds
ratio 
0,052,211,001,49Alverine/sWittmanAlverine/s
0,0 52,2 11,0 01,4 9Alverine/s
0,971,510,650,99HyoscineShaferHyoscine
0,9 71,5 10,6 50,9 9Hyoscine
0,612,110,280,77MebeverineKruisMebeverine
0,2413,660,522,67MebeverineSeccoMebeverine
0,0213,541,214,05Tarsmann-JonesMebeverine
0,1 43,4 10,8 41,6 9Mebeverine
0,039,521,153,31OtiloniumBarbierOtilonium
0,003,001,221,91OtiloniumBattagliaOtilonium
0,022,711,111,73OtiloniumClaveOtilonium
0,022,631,081,68OtiloniumGlendeOtilonium
0,0 02,3 61,4 31,8 4Otilonium
0,078,100,932,75PinaveriumDelmontPinaverium
0,0 78,1 00,9 32,7 5Pinaverium
0,842,000,571,07Pinaverium/sRemes-TrochePinaverium/s
0,8 42,0 00,5 71,0 7Pinaverium/s
0,792,460,310,87TrimebutineFieldingTrimebutine
0,1322,110,673,86TrimebutineMoshalTrimebutine
0,5 83,1 40,5 31,2 8Trimebutine
0,0 01,8 01,2 81,5 2Overall
0,0 1 0,1 1 10 10 0
Favours Placebo       Favours Treatmen t
Mebeverine
p-Value
Uppe r
limit 
Lower
limit 
Figure  5  Efﬁcacy  of  antispasmodics  on  pain  relief.  The  vertical  bars  represent  the  difference  in  the  response  rates  between
antispasmodics  (Treatment)  and  placebo.  The  white  circles  represent  the  OR  and  the  horizontal  lines  the  95%CI.  Overall  response
of each  type  of  antispasmodic  is  represented  by  the  black  diamonds.  Antispasmodics  were  effective  on  abdominal  pain  (Overall).
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1.49-2.77)  and  the  alverine/simethicone  combination  1.76
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relief,  alverine/simethicone  1.48  (95%  CI  1.00-2.19)  and
otilonium  1.83  (95%  CI  1.43-2.34)  demonstrated  signif-
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combination  of  pinaverium  bromide/simethicone  came  to
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Figure  6  Efﬁcacy  of  antispasmodics  on  abdominal  distention/bloa
rates between  antispasmodics  (Treatment)  and  placebo.  The  white
Overall response  of  each  type  of  antispasmodic  is  represented  by  the
distension/bloating  (Overall).  Speciﬁcally  by  type  of  antispasmodics,
was effective. were  effective.
cone.
nteresting  conclusions.  They  reported  that  pinaverium  bro-
ide/simethicone  was  effective  for  relieving  abdominal
ain  in  patients  with  active  IBS23 and  in  improving  bloating,24
ut  not  visible  abdominal  distension.  These  results  suggest
n  effect  on  visceral  perception.24 However,  the  published
bstracts  did  not  contain  the  data  necessary  for  the  cur-
ent  meta-analysis.  Therefore,  the  authors  were  contacted
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Rigure  7  Adverse  events.  There  were  no  differences  in  the  
pasmodics shown  to  be  safe.
or  the  completion  of  the  required  information.  This  is  the
rst  meta-analysis  to  incorporate  the  combination  of  anti-
pasmodics  with  an  anti-foaming  agent  that  may  constitute
 new  therapeutic  option.
The  combination  pinaverium/simethicone  resulted  in  an
R  of  1.45  (95%  CI  1.11-3.91)  for  bloating.  The  effect  with
he  addition  of  simethicone  was  greater  than  that  of  the
ntispasmodic  alone,  and  was  similar  to  the  effect  shown  by
he  alverine/simethicone  combination.  The  NNT,  calculated
rom  the  systematic  review  or  meta-analysis  of  randomized
linical  trials,  is  a  valuable  aid  in  making  clinical  decisions.18
he  NNT  was  recently  included  in  a  meta-analysis  of  medi-
ations  to  treat  IBS.25 Results  showed  a wide  range  of  NNT
alues;  from  4  to  20  for  5-HT3  antagonists  and  5HT4  agonists.
ther  analyses  also  included  antispasmodic  medications21
ith  a  wide  NNT  range;  from  3  to  25  depending  on  the  par-
icular  antispasmodic  tested.  We  only  calculated  the  NNT  for
he  global  assessment  and  pain  relief  in  those  medications
ith  a  signiﬁcant  OR  and  95%  CI.  We  found  that  the  antispas-
odics  with  the  lowest  NNT  to  achieve  global  improvement
ere  otilonium  and  the  alverine/simethicone  combination;
n  NNT  of  7  for  otilonium  and  8  for  the  combination.  For
ain  relief,  the  NNT  was  7  for  otilonium  and  11  for  alver-
ne/simethicone.  The  NNT  from  a  meta-analysis  should  be
iewed  with  caution,26 since  these  data  vary  according  to
atient  baseline  risk  and  this  could  be  signiﬁcantly  different
mong  the  trials  included  in  the  analysis.
The  weaknesses  in  this  meta-analysis  were  the  variability
mong  the  groups  of  patients  across  different  trials  and  the
nsufﬁciency  of  data  such  as  treatment  adherence  and
he  length  of  time  during  which  each  patient  took  the  med-
cations.
onclusionshe  lack  of  methodological  coherence  in  trials  published
efore  1995  makes  it  difﬁcult  to  reach  ﬁnal  conclusions
bout  the  efﬁcacy  of  certain  medications.  Publication  of  the
ome  II  and  III  trial  design  recommendations  for  functionalof  adverse  events  between  antispasmodics  and  placebo.  Anti-
owel  disorders  is  an  advance  in  the  methodological  qual-
ty  of  antispasmodic  trials;  however,  few  of  them  include
he  recent  diagnostic  criteria  in  their  design.  Antispas-
odic  agents  are  better  than  placebo  for  treating  IBS,  with
lmost  no  serious  adverse  events.  The  alverine/simethicone
ombination  and  otilonium  showed  a  NNT  of  7  to  11  with
igniﬁcant  results  for  global  assessment  and  pain  relief.
inaverium/simethicone  also  showed  effectiveness  in  reliev-
ng  bloating  and  had  better  results  than  pinaverium  alone.
uture  clinical  investigations  should  include  the  combina-
ion  of  antispasmodics  and  anti-foaming  agents  to  improve
he  clinical  effect  of  antispasmodics.
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